The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Maiborodin I.V.

Institute of Molecular Pathology and Pathomorphology of the Federal Research Center for Fundamental and Translational Medicine;
Institute of Chemical Biology and Fundamental Medicine

Klimachev I.V.

Altai State Medical University

Sheplev B.V.

Institute of Molecular Pathology and Pathomorphology of the Federal Research Center for Fundamental and Translational Medicine

Krasil’nikov S.E.

Institute of Molecular Pathology and Pathomorphology of the Federal Research Center for Fundamental and Translational Medicine

Maiborodina V.I.

Institute of Molecular Pathology and Pathomorphology of the Federal Research Center for Fundamental and Translational Medicine

Peculiarities of angiogenesis in clear cell renal cancer

Authors:

Maiborodin I.V., Klimachev I.V., Sheplev B.V., Krasil’nikov S.E., Maiborodina V.I.

More about the authors

Read: 1996 times


To cite this article:

Maiborodin IV, Klimachev IV, Sheplev BV, Krasil’nikov SE, Maiborodina VI. Peculiarities of angiogenesis in clear cell renal cancer. Russian Journal of Archive of Pathology. 2024;86(4):64‑70. (In Russ.)
https://doi.org/10.17116/patol20248604164

Recommended articles:
Endo­metrial vascularisation in hype­rplasia without atypia. Russian Journal of Archive of Pathology. 2025;(6):28-33
Influence of limb reva­scularization and therapeutic angiogenesis on concentration of angiogenic factors. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):539-546

References:

  1. Fateri C, Peta A, Limfueco L, Bui TL, Kar N, Glavis-Bloom J, Roth B, Landman J, Houshyar R. Novel retroperitoneal neovascularity scoring system in renal cell carcinoma tumor staging. J Endourol. 2023;37(3):367-373.  https://doi.org/10.1089/end.2022.0338
  2. Park KY, Hefti HO, Liu P, Lugo-Cintrón KM, Kerr SC, Beebe DJ. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma. Integr Biol (Camb). 2021;13(11):259-268.  https://doi.org/10.1093/intbio/zyab018
  3. Dell’Atti L, Bianchi N, Aguiari G. New therapeutic interventions for kidney carcinoma: looking to the future. Cancers (Basel). 2022;14(15):3616. https://doi.org/10.3390/cancers14153616
  4. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. The state of cancer care for the population of Russia in 2019. Moscow: MNIOI im. P.A. Herzen — branch of the Federal State Budgetary Institution «National Medical Research Center of Radiology» of the Ministry of Health of Russia; 2020. (In Russ.).
  5. Shevchenko AN, Breus AA, Neskubina IV, Dzhenkova EA, Filatova EV, Shvyrev DA. Evaluation of the prognostic significance of some biological factors in local and generalized clear cell renal cancer. South Russian Journal of Cancer. 2020;1(1):6-22. (In Russ.). https://doi.org/10.37748/2687-0533-2020-1-1-1
  6. Yan H, Zhu L, Zhang J, Lin Z. Histone demethylase KDM4D inhibition suppresses renal cancer progression and angiogenesis through JAG1 signaling. Cell Death Discov. 2021;7(1):284.  https://doi.org/10.1038/s41420-021-00682-y
  7. Zhang Y, Chen Z, Chen JG, Chen XF, Gu DH, Liu ZM, Gao YD, Zheng B. Ceruloplasmin overexpression is associated with oncogenic pathways and poorer survival rates in clear-cell renal cell carcinoma. FEBS Open Bio. 2021;11(11):2988-3004. https://doi.org/10.1002/2211-5463.13283
  8. Liu W, Yan B, Yu H, Ren J, Peng M, Zhu L, Wang Y, Jin X, Yi L. OTUD1 stabilizes PTEN to inhibit the PI3K/AKT and TNF-alpha/NF-kappaB signaling pathways and sensitize ccRCC to TKIs. Int J Biol Sci. 2022;18(4):1401-1414. https://doi.org/10.7150/ijbs.68980
  9. Dumond A, Montemagno C, Vial V, Grépin R, Pagès G. Anti-vascular endothelial growth factor C antibodies efficiently inhibit the growth of experimental clear cell renal cell carcinomas. Cells. 2021;10(5):1222. https://doi.org/10.3390/cells10051222
  10. Yoshida T, Ohe C, Ikeda J, Atsumi N, Ohsugi H, Sugi M, Higasa K, Saito R, Tsuta K, Matsuda T, et al. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. J Immunother Cancer. 2021;9(9):e002922. https://doi.org/10.1136/jitc-2021-002922
  11. Mubarak M, Al-Gharaibeh N, Sommaruga S, Li J, Vortmeyer AO. Histological tracking into the third dimension: evolution of early tumorigenesis in VHL kidney. J Kidney Cancer VHL. 2021; 8(3):5-14.  https://doi.org/10.15586/jkcvhl.v8i3.189
  12. Takao S, Ushijima Y, Motomura Y, Sakamoto K, Hirakawa M, Nishie A, Mimori K, Yamashita Y, Tsutsumi T, Ishigami K. Radiology- and gene-based risk stratification in small renal cell carcinoma: a preliminary study. PLoS One. 2021;16(9):e0256471. https://doi.org/10.1371/journal.pone.0256471
  13. Xin S, Sun X, Jin L, Zhou Z, Liu X, Li W, Mei W, Zhang J, Zhang B, Yao X, et al. Identifying the potential role and prognostic value of the platelet-derived growth factor pathway in kidney renal clear cell carcinoma. J Oncol. 2022;2022:9498010. https://doi.org/10.1155/2022/9498010
  14. Seo SU, Woo SM, Im SS, Jang Y, Han E, Kim SH, Lee H, Lee HS, Nam JO, Gabrielson E, et al. Cathepsin D as a potential therapeutic target to enhance anticancer drug-induced apoptosis via RNF183-mediated destabilization of Bcl-xL in cancer cells. Cell Death Dis. 2022;13(2):115.  https://doi.org/10.1038/s41419-022-04581-7
  15. Karpova Y, Guo D, Makhov P, Haines AM, Markov DA, Kolenko V, Tulin AV. Poly(ADP)-ribosylation inhibition: a promising approach for clear cell renal cell carcinoma therapy. Cancers (Basel). 2021;13(19):4973. https://doi.org/10.3390/cancers13194973
  16. Meng X, Yuan H, Li W, Xiao W, Zhang X. Biomarker screening and prognostic significance analysis for renal cell carcinoma. Int J Gen Med. 2021;14:5255-5267. https://doi.org/10.2147/IJGM.S325347
  17. Bekku K, Tsugawa T, Tsuboi K, Noda G, Inoue Y, Murao W, Ebara S. Molecular-targeted therapy for metastatic renal cell carcinoma as first-line therapy: a single institution 13-year experience. Acta Med Okayama. 2022;76(4):465-472.  https://doi.org/10.18926/AMO/63906
  18. Topal A, Sayın S, Gokyer A, Kucukarda A, Kostek O, Bekir Hacıoglu M, Uzunoglu S, Erdogan B, Cicin I. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience. J BUON. 2021;26(4): 1628-1634.
  19. Ohe C, Yoshida T, Amin MB, Atsumi N, Ikeda J, Saiga K, Noda Y, Yasukochi Y, Ohashi R, Ohsugi H, et al. Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes. Mod Pathol. 2022;35(6):816-824.  https://doi.org/10.1038/s41379-021-00982-9
  20. Denize T, Farah S, Cimadamore A, Flaifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, et al. Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in patients with metastatic renal cell carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2022;28(4):748-755.  https://doi.org/10.1158/1078-0432.CCR-21-3088
  21. Roussel E, Kinget L, Verbiest A, Boeckx B, Zucman-Rossi J, Couchy G, Caruso S, Baldewijns M, Joniau S, Van Poppel H, et al. Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. Acta Oncol. 2021;60(11):1499-1506. https://doi.org/10.1080/0284186X.2021.1962971
  22. Roussel E, Verbiest A, Kinget L, Boeckx B, Zucman-Rossi J, Couchy G, Caruso S, Job S, de Reyniès A, De Wever L, et al. Molecular subtypes and gene expression signatures as prognostic features in fully resected clear cell renal cell carcinoma: a tailored approach to adjuvant trials. Clin Genitourin Cancer. 2021; 19(6):e382-e394. https://doi.org/10.1016/j.clgc.2021.07.005
  23. Situ Y, Xu Q, Deng L, Zhu Y, Gao R, Lei L, Shao Z. System analysis of VEGFA in renal cell carcinoma: The expression, prognosis, gene regulation network and regulation targets. Int J Biol Markers. 2022;37(1):90-101.  https://doi.org/10.1177/17246008211063501
  24. Udayakumar D, Zhang Z, Xi Y, Dwivedi DK, Fulkerson M, Haldeman S, McKenzie T, Yousuf Q, Joyce A, Hajibeigi A, et al. Deciphering intratumoral molecular heterogeneity in clear cell renal cell carcinoma with a Radiogenomics Platform. Clin Cancer Res. 2021;27(17):4794-4806. https://doi.org/10.1158/1078-0432.CCR-21-0706
  25. Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grepin R, Rioux-Leclercq N, et al. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy. BJU Int. 2022;129(1):80-92.  https://doi.org/10.1111/bju.15506
  26. Li K, Tan L, Li Y, Lyu Y, Zheng X, Jiang H, Zhang X, Wen H, Feng C. Cuproptosis identifies respiratory subtype of renal cancer that confers favorable prognosis. Apoptosis. 2022;27(11-12):1004-1014. https://doi.org/10.1007/s10495-022-01769-2
  27. Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, Maruzzo M, Mosca A, Pisano C, Verzoni E, et al. Combination therapy in renal cell carcinoma: the best choice for every patient? Curr Oncol Rep. 2021;23(12):147.  https://doi.org/10.1007/s11912-021-01140-9
  28. Graham J, Wells JC, Dudani S, Gan CL, Donskov F, Lee JL, Kollmannsberger CK, Meza L, Beuselinck B, Hansen A, et al. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. Eur J Cancer. 2022;171:124-132.  https://doi.org/10.1016/j.ejca.2022.05.002
  29. Swearson S, Rataan AO, Eliason S, Amendt BA, Zakharia Y, Salem AK, Ho T, Rustum YM. MicroRNA expression in clear cell renal cell carcinoma cell lines and tumor biopsies: potential therapeutic targets. Int J Mol Sci. 2022;23(10):5604. https://doi.org/10.3390/ijms23105604
  30. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, et al. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022;14(641):eabm6420. https://doi.org/10.1126/scitranslmed.abm6420
  31. Xie Y, Shangguan W, Chen Z, Zheng Z, Chen Y, Zhong Q, Zhang Y, Yang J, Zhu D, Xie W. Establishment of sunitinib-resistant xenograft model of renal cell carcinoma and the identification of drug-resistant hub genes and pathways. Drug Des Devel Ther. 2021;15:5061-5074. https://doi.org/10.2147/DDDT.S343718
  32. Marona P, Górka J, Kwapisz O, Jura J, Rys J, Hoffman RM, Miekus K. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation. Cell Death Dis. 2022;13(9):814.  https://doi.org/10.1038/s41419-022-05251-4
  33. Principe DR, Schulte BC, Kamath SD, Munshi HG. Glandular metastases from renal cell carcinoma show poor clinical responses to immune checkpoint inhibition but durable responses to angiogenesis inhibitors. BMJ Case Rep. 2021;14(6):e243259. https://doi.org/10.1136/bcr-2021-243259

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.